Affiliation:
1. Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China
2. Research Unit of Radiation Oncology Chinese Academy of Medical Sciences Jinan China
3. Department of Oncology Renmin Hospital of Wuhan University Wuhan China
4. Cheeloo College of Medicine Shandong University Jinan China
Abstract
AbstractRecent studies have highlighted the pivotal roles of T cell transcription factors TCF‐1 and TOX in modulating the immune response in cancer, with TCF‐1 maintaining CD8+ T cell stemness and TOX promoting T cell exhaustion. The prognostic significance of these factors in lung adenocarcinoma (LUAD) remains a critical area of investigation. The retrospective study included 191 patients with LUAD who underwent surgery, of whom 83% were in stages II and III. These patients were divided into exploratory (n = 135) and validation (n = 56) groups based on the time of diagnosis. Multiplex fluorescence immunohistochemistry was used to examine the infiltration levels of CD8+ T cells, TCF1+ CD8+ T cells, and TOX+ CD8+ T cells. The percentage of CD8+ T cells in tumor was markedly lower than that in stroma (p < 0.05). In tumor‐draining lymph nodes (TDLNs) invaded by tumor, the proportion of stem‐like TCF1+ CD8+ T cells was significantly decreased (p < 0.01). Importantly, higher infiltration levels of CD8+ T cells and TCF1+ CD8+ T cells were associated with improved disease‐free survival (DFS) (p = 0.009 and p = 0.006, respectively) and overall survival (OS) (p = 0.018 and p = 0.010, respectively). This study underscores the potential of TCF1+ CD8+ T cells as prognostic biomarkers in LUAD, providing insights into the tumor immune microenvironment and guiding future therapeutic strategies.
Funder
National Natural Science Foundation of China
Natural Science Foundation of Shandong Province